<DOC>
	<DOCNO>NCT02949895</DOCNO>
	<brief_summary>A study evaluate safety tolerability BMS-986012 patient small cell lung cancer</brief_summary>
	<brief_title>Study BMS-986012 Subjects With Small Cell Lung Caner</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<criteria>For information regard BristolMyers Squibb Clinical Trial participation , please visit www.BMSStudyConnect.com Histological cytological confirm small cell lung cancer ( SCLC ) Eastern Cooperative Oncology Group Performance Status 01 least one measurable lesion amenable resection . Adequate organ function Symptomatic central nervous system ( CNS ) metastases Grade â‰¥ 2 peripheral neuropathy Uncontrolled significant cardiac disease Active chronic infection Human Immunodeficiency Virus ( HIV ) , Hepatitis B Virus ( HBV ) , Hepatitis C Virus ( HCV ) Other protocol define inclusion/exclusion criterion could apply</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>